Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: A randomised controlled trial

Current Medical Research and Opinion

Volumn 22, Issue 6, 2006, Pages 1085-1092

  Escribano, Amparo ^a   Tutuncu, A ^b   Lohr I ^b   Carlholm, M ^c   Polanowski, T ^c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b SkyePharma AG   (Switzerland)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Asthma; Budesonide; Chlorofluorocarbon (CFC); Clinical equivalence; Hydrofluoroalkane (HFA); Inhaler; Paediatric

Indexed keywords

BUDESONIDE; CHLOROFLUOROCARBON;

ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; EXPIRATORY FLOW RATE; EXPIRATORY RESERVE VOLUME; FEMALE; HEADACHE; HOARSENESS; HUMAN; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; THRUSH; VITAL CAPACITY;

AEROSOL PROPELLANTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; CHLOROFLUOROCARBONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED; MALE; METERED DOSE INHALERS; PEAK EXPIRATORY FLOW RATE; TREATMENT OUTCOME;

EID: 33745728028     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X104812     Document Type: Article

References (23)

1. Global Initiative for Asthma: Global strategy for asthma management and prevention. GINA workshop report. Bethesda, MD: National Institutes for Health. NIH Publication No. 02-3659, 1995 (updated 2004)
2. National Heart, Lung, and Blood Institute, National Institutes of Health. World Health Organization. Global initiative for asthma. Pocket guide for asthma management. Bethesda: NH/NHLBI, 1998. Publication No. 96-3659B
3. National Asthma Education Prevention Program (NAEPP). Expert panel report: guidelines for the diagnosis and management of asthma - update on selected topics. J Allergy Clin Immunol 2002;110:S141-219
4. Cripps A, Riebe M, Schulze M, et al. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000;94 (Suppl B):S3-9
5. Mueller-Walz R, Gilchrist P, Neiderlaender C. In-vitro characterization of SkyePharma budesonide HFA metered dose inhaler. J Aerosol Med 2003;16:193 [abstract 25]
6. SkyePharma. Budesonide HFA metered dose inhaler. Data on file
7. Masoli M, Wetherall M, Holt S, et al. Budesonide once versus twice-daily administration: meta-analysis. Respirology 2004;9:528-34
8. Selroos O, Edsbäcker S, Hultquist C. Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation. J Asthma 2004;41:771-90
9. Sheffer AL, Silverman M, Woolcock AJ, et al. Long-term safety of once-daily budesonide in patients with early onset mild persistent asthma: results of the Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study. Ann Allergy Asthma Immunol 2005;94:48-54
10. Szefler SJ, Lyzell E, Fitzpatrick S, et al. Safety profile of budesonide inhalation suspension in the pediatric population: worldwide experience. Ann Allergy Asthma Immunol 2004;93:83-90
11. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994;88:373-81
12. Haahtela T, Järvinen M, Kava T, et al. Comparison of a beta2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. New Engl J Med 1991;325:388-92
13. Juniper EF, Kline PA, Vanzieleghem MA, et al. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J 1990;3:1122-7
14. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al., Dutch CNSLD study group. Effects of 22 months treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992;146:547-54
15. van Essen Zandvliet EE. Long-term intervention in childhood asthma - the Dutch study results. Monaldi Arch Chest Dis 1995;50:201-7
16. Pedersen S, Ramsgaard-Hansen O. Budesonide treatment of moderate and severe asthma in children: a dose response study. J Allergy Clin Immunol 1995;95:29-33
17. Blackwelder WC. Proving the null hypothesis in clinical trials. Controlled Clin Trials 1982;3:345-53
18. Shapiro G, Bronsky EA, LaForce CF, et al. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr 1998;132:976-82
19. Borgström L. The pharmacokinetics of inhaled hydrofluoroalkane formulations. J Allergy Clin Immunol 1999;104:S246-9
20. Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999;104:1215-22
21. Kunka R, Andrews S, Pimazzoni M, et al. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respir Med 2000;94(Suppl B):S10-6
22. Ram FS, Brocklebank DM, White J, et al. Pressurised metered dose inhalers versus all other hand-held inhaler devices to deliver beta-2 agonist bronchodilators for non-acute asthma. Cochrane Database Syst Rev 2002;(1):CD002158
23. Langley SJ, Houghton CM, Singh SD. Bronchoprotective and bronchodilator effects of an HFA pMDI vs a CFC pMDI and a DPI containing formoterol in asthma patients. Respiration 2005;72(Suppl 1):35-7